2022
Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis
Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.Peer-Reviewed Original ResearchConceptsNonseminomatous germ cell tumorsCancer-specific survivalGerm cell tumorsCell tumorsStage groupPediatric patientsAdolescent patientsYoung adultsStage IAdvanced nonseminomatous germ cell tumorsSurvival analysisAge groupsWorse cancer-specific survivalCox proportional hazards modelTesticular germ cell tumorsEnd Results (SEER) databaseExcellent survival outcomesStage III tumorsExcellent oncologic outcomesImportant prognostic factorKaplan-Meier curvesCommon solid malignancyProportional hazards modelNSGCT patientsOncologic outcomes
2021
Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era
Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall’Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second‐line antiandrogen therapy era. Cancer Medicine 2021, 10: 7909-7920. PMID: 34713977, PMCID: PMC8607264, DOI: 10.1002/cam4.4074.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic prostate cancer patientsProstate cancer patientsProstate cancerCancer patientsSecond-line antiandrogen therapyProstate cancer-specific survivalCancer-specific survivalNew treatment agentsTherapy eraVisceral metastasesAntiandrogen therapySEER databaseSurvival benefitSurvival outcomesPatientsCancerSurvivalTreatment agentsMenMetastasisTherapyMonthsComparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomesCollagen type VI-α1 and 2 repress the proliferation, migration and invasion of bladder cancer cells
Piao X, Hwang B, Jeong P, Byun Y, Kang H, Seo S, Kim W, Lee J, Ha Y, Lee Y, Kim I, Choi Y, Cha E, Moon S, Yun S, Kim W. Collagen type VI-α1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal Of Oncology 2021, 59: 37. PMID: 33982770, DOI: 10.3892/ijo.2021.5217.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCell Line, TumorCell MovementCell ProliferationCollagen Type VIG1 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansMiddle AgedP38 Mitogen-Activated Protein KinasesPhosphorylationProto-Oncogene Proteins c-aktSignal TransductionTranscription FactorsUrinary Bladder NeoplasmsConceptsNon-muscle invasive BCaExtracellular matrixMRNA expressionEJ cellsBladder cancer microenvironmentTissue samplesHeterogeneous tumor cell populationsCell cycle arrestReverse transcription-quantitative PCRTumor-suppressive effectsBladder cancer cellsP38 MAPK phosphorylationTranscription-quantitative PCRCollagen typesRisk stratificationInvasive BCaTumor infiltrationTumor cell populationBCa pathogenesisMMP-9MAPK phosphorylationAkt phosphorylationCycle arrestNormal controlsMatrix metalloproteinase
2020
Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation
Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTF′s 2012 prostate‐specific antigen–based prostate cancer screening recommendation. Cancer 2020, 126: 5114-5123. PMID: 32888321, DOI: 10.1002/cncr.33179.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceProstate cancerSurvival disparitiesWhite menProstate cancer screening recommendationsBlack menPCa-specific survivalAdverse clinical featuresCancer screening recommendationsEnd Results (SEER) databaseYear of diagnosisProstate-specific antigenClinical featuresScreening recommendationsResults databaseSurvival outcomesGrade CGrade D.White individualsMenRacial discrepanciesSurvivalTask ForceOutcomesTotalIndividual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer
Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, Lu‐Yao G. Individual and joint effects of metformin and statins on mortality among patients with high‐risk prostate cancer. Cancer Medicine 2020, 9: 2379-2389. PMID: 32035002, PMCID: PMC7131852, DOI: 10.1002/cam4.2862.Peer-Reviewed Original ResearchConceptsHigh-risk PCaPCa mortalityCause mortalityPopulation-based retrospective cohort studyHigh-risk prostate cancerCox proportional hazards modelRetrospective cohort studyHigh-risk patientsFirst human studyProstate cancer metastasisCause of deathProportional hazards modelPre-clinical studiesMetformin useCohort studyProstate cancerStatinsHazards modelHuman studiesPatientsMetforminSignificant associationMortalityPropensity scoreCancer metastasis
2019
DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome
Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaDisease-free survivalAdvanced clear cell renal cell carcinomaDDR pathway alterationPathway alterationsLocalized Clear Cell Renal Cell CarcinomaDecreased disease-free survivalTCGA databaseShorter disease-free survivalCopy number alterationsTherapeutic agentsCox regression analysisT3-4 diseaseClear-Cell RenalRenal cell carcinomaDDR pathwaysPresence of mutationsT3a diseaseNeoadjuvant therapyOverall survivalPoor outcomeCell carcinomaCommon subtypeDisease progressionKidney cancerSimilar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer
Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer. BMC Urology 2019, 19: 33. PMID: 31060606, PMCID: PMC6501301, DOI: 10.1186/s12894-019-0453-9.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerDDR pathway alterationProstate cancerPathway alterationsMetastatic castration-resistant prostate cancerSerum prostate-specific antigenHigh-risk diseaseMetastatic prostate cancerLower overall survivalPathway gene mutationsProstate-specific antigenPotential therapeutic targetUnited States National Cancer InstituteNational Cancer InstituteCRPC patientsCancer Genome AtlasOverall survivalSimilar incidenceTumor stageUnivariate analysisCancer InstituteTherapeutic targetSpecific antigenPARP inhibitorsPathway statusUrinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer 2019, 17: e704-e711. PMID: 31088707, DOI: 10.1016/j.clgc.2019.04.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkers, TumorBone Morphogenetic Protein 4Cell-Free Nucleic AcidsDisease ProgressionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, Tumor SuppressorGTPase-Activating ProteinsHumansMaleMiddle AgedNuclear ProteinsPrognosisSurvival AnalysisUrinary Bladder NeoplasmsConceptsProgression-free survivalCox regression analysisRecurrence-free survivalDisease recurrenceBladder cancerNon-muscle invasive bladder cancerInvasive bladder cancer patientsWorse progression-free survivalMultivariate Cox regression analysisWorse recurrence-free survivalKaplan-Meier analysisKaplan-Meier curvesBladder cancer patientsRegression analysisUrinary cell-free DNAValuable novel biomarkersCell-free DNANMIBC patientsClinical outcomesCancer patientsDisease progressionPrognostic markerReal-time PCRNovel biomarkersIndependent factors
2018
Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria
Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology Seminars And Original Investigations 2018, 37: 86-96. PMID: 30446454, DOI: 10.1016/j.urolonc.2018.10.023.Peer-Reviewed Original ResearchConceptsBladder cancerUrinary cell-free DNACell-free DNAScreening groupHematuria patientsValidation cohortPredictive valueUrine-based markersNegative predictive valuePositive predictive valueGood diagnostic performanceStudy cohortBC patientsUrological cancersNoninvasive biomarkersPatientsScore indexDiagnostic valueHematuriaExpression level ratioLiquid biopsyCohortDiagnostic performanceCancerDS-indexComparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2017
Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patientLocal Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer
Parikh R, Byun J, Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer. The Prostate 2017, 77: 559-572. PMID: 28093791, DOI: 10.1002/pros.23294.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMetastatic prostate cancerLocal therapyOverall survivalProstate cancerRadiation therapyMultivariable Cox proportional hazards modelsLower co-morbidity scoreFive-year overall survivalCox proportional hazards modelAcademic/research programCo-morbidity scoreSuperior overall survivalNode-negative statusProspective clinical trialsKaplan-Meier methodLower T stagePatterns of careProportional hazards modelPropensity-score matchingPrimary diseaseT stageMedicare insuranceGleason scoreCancer Database
2016
Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice
Davis R, Salmasi A, Koprowski C, Kim S, Kwon Y, Faiena I, Patel N, Elsamra S, Kim I. Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice. Clinical Genitourinary Cancer 2016, 14: e617-e622. PMID: 27188968, DOI: 10.1016/j.clgc.2016.04.010.Peer-Reviewed Original ResearchConceptsExtracapsular extensionProstate cancerRadical prostatectomyMp-MRINegative predictive valuePositive predictive valuePredictive valuePartin tablesMultiparametric magnetic resonance imagingNerve-sparing approachPreoperative mp-MRID'Amico risk groupsLarge referral centerHigh-risk groupDatabase of menMagnetic resonance imagingReferral centerStaging modalitiesD'Amico criteriaFusion biopsyOverall prevalenceRisk groupsMultiparametric MRISurgeon's decisionResonance imaging
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsRefining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score
Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score. Asian Journal Of Andrology 2015, 19: 20-25. PMID: 26620454, PMCID: PMC5227667, DOI: 10.4103/1008-682x.159715.Peer-Reviewed Original ResearchMeSH KeywordsAgedDatabases, FactualDisease-Free SurvivalHumansKallikreinsKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPractice Guidelines as TopicProstate-Specific AntigenProstatectomyProstatic NeoplasmsRadiation OncologyRadiotherapy, AdjuvantRetrospective StudiesSocieties, MedicalUnited StatesUrologyConceptsPositive surgical marginsGleason score 6Adjuvant radiotherapyGleason score 8BCR-free survivalRadical prostatectomyBiochemical recurrenceAmerican Urological AssociationPathologic stageGleason scoreScore 6BCR rateSurgical marginsScore 8Urological AssociationPathologic Gleason score 8Multivariate Cox regression analysisPathologic Gleason scoreSurgical margin statusCox regression analysisRadiation Oncology guidelinesAmerican SocietyASTRO guidelineIndependent predictorsMargin statusSafety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients
Modi P, Kwon Y, Patel N, Dinizo M, Farber N, Zhao P, Salmasi A, Parihar J, Ginsberg S, Ha Y, Kim I. Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of 751 Patients. Journal Of Endourology 2015, 29: 1148-1151. PMID: 25891967, DOI: 10.1089/end.2015.0094.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyInsufflation pressureComplication rateHemoglobin levelsOperative timeRadical prostatectomyControl groupShort-term perioperative outcomesPostoperative hemoglobin levelsGlomerular filtration rateMean hemoglobin levelDatabase of patientsHigh complication rateNumber of patientsUse of pneumoperitoneumExperimental groupHigh insufflation pressurePerioperative outcomesRenal functionBlood lossPneumoperitoneum pressureFiltration rateSignificant short-term effectPatientsVenous oozingLower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics
Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.Peer-Reviewed Original ResearchConceptsProstate cancerClinicopathological characteristicsElevated prostate-specific antigen levelsProstate-specific antigen levelBenign prostatic hyperplasia patientsNon-metastatic diseaseAggressive clinicopathologic featuresLow PSA levelsSpecific antigen levelsProstatic hyperplasia patientsAggressive clinicopathological characteristicsLow Gleason scoreHuman prostate cancerCharacteristic curve analysisProstate cancer susceptibilityPSA levelsMetastatic diseasePCa patientsClinicopathologic featuresHyperplasia patientsAntigen levelsGleason scoreClinicopathological parametersPCa tissuesReal-time PCRRegional Cost Variations of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy
Faiena I, Dombrovskiy V, Modi P, Patel N, Patel R, Salmasi A, Parihar J, Singer E, Kim I. Regional Cost Variations of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy. Clinical Genitourinary Cancer 2015, 13: 447-452. PMID: 26065923, PMCID: PMC5176017, DOI: 10.1016/j.clgc.2015.05.004.Peer-Reviewed Original ResearchCorrespondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses
Virtue S, Manne S, Kashy D, Heckman C, Zaider T, Kissane D, Kim I, Lee D, Olekson G. Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses. European Journal Of Cancer Care 2015, 24: 827-839. PMID: 25807856, PMCID: PMC4733598, DOI: 10.1111/ecc.12316.Peer-Reviewed Original ResearchConceptsFruit/vegetable consumptionProstate cancer survivorsCancer survivorsPhysical activityVegetable consumptionHealthy dietGreater patientCouple-based interventionsProstate cancerControl trialHealth behaviorsHealthy behaviorsSurvivorsExercise behaviorBaseline dataPatientsDietSelf-report measuresSpousal relationshipHigher relationship satisfactionSpousesPast yearHigh levelsRelationship satisfactionActivity